JAZZ's Quality Score fell 3 points on Mon, Nov 2, to 7.
Follow JAZZ's trial news. Pro members can get an alert when Jazz Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 59% in a year while the S&P 500 rose 12%.
“Xywav product sales increased by 12% in 2025 compared to 2024, primarily due to increased sales volumes of 14% and, to a lesser extent”
| The company | A $941M profit |
| Latest filing | 8-K, Nov 2 |
ReportToday after the close: sales of $1.2B; a loss of $7.48 a share. Raised its outlook for the year. Past reports ›
Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.
Expected to report Tue Feb 23, after the close
1 more date ahead: the conference, for Pro members.
No shelf registration or at-the-market program on file in the last three years.
CEO Renee D. Gala sold 2,000 shares on Oct 6, under a planned sale. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
JAZZ is #52 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 52 |
Net income over four quarters: JAZZ $941M, ONC $656M, SUPN -$110M.
Expected to report Tue Feb 23, after the close (in 113 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $1.2B, 10% more than a year ago; a loss of $7.48 a share, from a profit of $4.08.
“Total revenues increased 10% YoY in 3Q26 primarily due to higher Xywav, Zepzelca and Ziihera net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025.”
JAZZ's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $4.775B to $4.850B |
“Zepzelca net product sales increased 32% YoY to $104 million in 3Q26, driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance extensive-stage small-cell lung cancer setting, partially offset by a decline in second-line use.”
From its results filing (SEC filing · Nov 2)
Sales grew 13% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.5% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 3, 2026 | +1.5% | +4.0% | +2.0% |
| May 5, 2026 | +7.4% | +7.7% | +7.3% |
| Feb 24, 2026 | +3.5% | +13.2% | +7.4% |
Sales grew every year from 2018 to 2025, to $4.3B. It lost money in 2025 after a profit in 2024.
3 insiders sold $2.8M across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: JAZZ is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
“The biopharmaceutical industry is highly competitive.”
JAZZ scores 7 today, which Breakaway calls Average. It is #52 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 59% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
JAZZ scores 7 today, which Breakaway calls Average (6 to 10). That is #52 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind JAZZ's 7.
3 insiders sold $2.8M across 3 filings in the last 6 months. No open-market buys on record. The newest is Samantha Pearce, EVP, Chief Commercial Officer, who sold $1.6M on May 28. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.